The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.
Please contact or connect with Regeneus via social media platforms below if you'd like further information.
To view the Edison Report, please visit:
http://abnnewswire.net/lnk/ZT58EC4E
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Contact
Sandra McIntoshCompany Secretary and Investor Relations
Tel: +61 2 9499 8010
Fax: +61 2 9499 8020
Mob: +61 450 253 059
Email: investors@regeneus.com.au
Related Companies
Related Industry Topics: